Monoclonal antibodies in cancer therapy
D Zahavi, L Weiner - Antibodies, 2020 - mdpi.com
Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …
The TRAIL to cancer therapy: Hindrances and potential solutions
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and
pathological conditions. Resistance to apoptosis is a hallmark of virtually all malignancies …
pathological conditions. Resistance to apoptosis is a hallmark of virtually all malignancies …
Engineered exosomes for studies in tumor immunology
Exosomes are a type of extracellular vesicle (EV) with diameters of 30–150 nm secreted by
most of the cells into the extracellular spaces and can alter the microenvironment through …
most of the cells into the extracellular spaces and can alter the microenvironment through …
Glycans as targets for drug delivery in cancer
Simple Summary Alterations in glycosylation are frequently observed in cancer cells.
Different strategies have been proposed to increase drug delivery to the tumor site in order …
Different strategies have been proposed to increase drug delivery to the tumor site in order …
[HTML][HTML] The current landscape of antibody-based therapies in solid malignancies
Over the past three decades, monoclonal antibodies (mAbs) have revolutionized the
landscape of cancer therapy. Still, this benefit remains restricted to a small proportion of …
landscape of cancer therapy. Still, this benefit remains restricted to a small proportion of …
Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
A Kusowska, M Kubacz, M Krawczyk… - International Journal of …, 2022 - mdpi.com
Despite the unquestionable success achieved by rituximab-based regimens in the
management of diffuse large B-cell lymphoma (DLBCL), the high incidence of …
management of diffuse large B-cell lymphoma (DLBCL), the high incidence of …
Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo
Abstract Drug-Free Macromolecular Therapeutics (DFMT) is a new paradigm in
macromolecular therapeutics that induces apoptosis in target cells by crosslinking receptors …
macromolecular therapeutics that induces apoptosis in target cells by crosslinking receptors …
Development of new bioactive molecules to treat breast and lung cancer with natural myricetin and its derivatives: A computational and SAR approach
Each biopharmaceutical research and new drug development investigation is targeted at
discovering novel and potent medications for managing specific ailments. Thus, to discover …
discovering novel and potent medications for managing specific ailments. Thus, to discover …
Coupling suspension trap**–based sample preparation and data-independent acquisition mass spectrometry for sensitive exosomal proteomic analysis
It has been a challenge to analyze minute amounts of proteomic samples in a facile and
robust manner. Herein, we developed a quantitative proteomics workflow by integrating …
robust manner. Herein, we developed a quantitative proteomics workflow by integrating …
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple …
H Chen, M Li, N Ng, E Yu, S Bujarski… - British Journal of …, 2021 - Wiley Online Library
Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms,
which may potentially include the programmed cell death ligand‐1 (PD‐L1): programmed …
which may potentially include the programmed cell death ligand‐1 (PD‐L1): programmed …